TriSalus Life Sciences Inc
NASDAQ:TLSI
TriSalus Life Sciences Inc
Cash from Operating Activities
TriSalus Life Sciences Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
TriSalus Life Sciences Inc
NASDAQ:TLSI
|
Cash from Operating Activities
-$40.8m
|
CAGR 3-Years
-186%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
Nextdoor Holdings Inc
NYSE:KIND
|
Cash from Operating Activities
-$20.2m
|
CAGR 3-Years
27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Flame Acquisition Corp
NYSE:SOC
|
Cash from Operating Activities
-$185.4m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Core Scientific Inc
NASDAQ:CORZ
|
Cash from Operating Activities
$42.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Symbotic Inc
NASDAQ:SYM
|
Cash from Operating Activities
-$58.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Rumble Inc
NASDAQ:RUM
|
Cash from Operating Activities
-$87m
|
CAGR 3-Years
-156%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
TriSalus Life Sciences Inc
Glance View
TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.
See Also
What is TriSalus Life Sciences Inc's Cash from Operating Activities?
Cash from Operating Activities
-40.8m
USD
Based on the financial report for Dec 31, 2024, TriSalus Life Sciences Inc's Cash from Operating Activities amounts to -40.8m USD.
What is TriSalus Life Sciences Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-186%
Over the last year, the Cash from Operating Activities growth was 19%. The average annual Cash from Operating Activities growth rates for TriSalus Life Sciences Inc have been -186% over the past three years .
You don't have any saved screeners yet